BioSystems and Micromechanics Interdisciplinary Research Group, Singapore-MIT Alliance in Research and Technology, 1 Create Way, #04-13/14, 138602 Singapore.
NUS Tissue Engineering Program, Life Sciences Institute, National University of Singapore, 27 Medical Drive1, DSO (Kent Bridge) Building, Level 4, 117510 Singapore.
Lab Chip. 2018 Mar 13;18(6):878-889. doi: 10.1039/c7lc01005b.
Mesenchymal stem cells (MSCs) have been shown as potential candidates for cell-based therapies for a diverse range of tissue regenerative applications. Therapeutic use of MSCs usually requires culture expansion, which increases the heterogeneity of MSCs in vitro, thus affecting the potency of the MSCs for more specific indications. The capacity for identifying and isolating special subsets of MSCs for treatment of specific diseases therefore holds great clinical significance. An important therapeutic application of MSC is for the regeneration of cartilage tissue. We and others have previously developed label-free microfluidic means to isolate subpopulations of culture expanded MSCs based on distinct biophysical characteristics. Here we utilize a spiral micro-channel device to separate culture expanded MSCs into five subgroups according to cell size, and study their proliferation and chondrogenesis at early, middle and late passages. Results show that in all passages, the medium-size subpopulation (cell size of 17-21 μm), compared to other subpopulations, displays significantly higher proliferation rate and chondrogenic capacity in terms of cartilage extracellular matrix formation. Also, the small cell subpopulation (average cell size of 11-12 μm) shows lower viability, and large cell subpopulation (average cell size 23-25 μm) expresses higher level of senescence-associated β-galactosidase. Finally, we show that repeated microfluidic exclusion of MSCs larger than 21 μm and smaller than 17 μm at every passage during continuous culture expansion result in selected MSCs with faster proliferation and better chondrogenic potential as compared to MSC derived from conventional expansion approach. This study demonstrates the significant merit and utility of size-based cell selection for the application of MSCs in cartilage regeneration.
间充质干细胞 (MSCs) 已被证明是细胞疗法的潜在候选者,可用于多种组织再生应用。MSCs 的治疗用途通常需要培养扩增,这会增加体外 MSCs 的异质性,从而影响 MSCs 针对更具体适应症的效力。因此,鉴定和分离用于治疗特定疾病的 MSC 特殊亚群的能力具有重要的临床意义。MSC 的一个重要治疗应用是软骨组织的再生。我们和其他人之前已经开发了无标记的微流控手段,根据独特的生物物理特性从培养扩增的 MSC 中分离亚群。在这里,我们利用螺旋微通道装置根据细胞大小将培养扩增的 MSC 分离成五个亚群,并研究它们在早期、中期和晚期传代时的增殖和软骨形成能力。结果表明,在所有传代中,与其他亚群相比,中等大小的亚群(细胞大小为 17-21μm)在软骨细胞外基质形成方面表现出更高的增殖率和软骨形成能力。此外,小细胞亚群(平均细胞大小为 11-12μm)表现出较低的活力,而大细胞亚群(平均细胞大小 23-25μm)表达出更高水平的衰老相关β-半乳糖苷酶。最后,我们表明,在连续培养扩增过程中,每传代一次就通过微流控排斥大于 21μm 和小于 17μm 的 MSC,可获得比传统扩增方法衍生的 MSC 增殖更快、软骨形成潜力更好的选择 MSC。这项研究证明了基于大小的细胞选择在软骨再生中应用 MSC 的显著优点和实用性。